Literature DB >> 7616365

Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A induction.

J C Fleishaker1, L K Pearson, G R Peters.   

Abstract

This study was conducted in eight healthy volunteers to assess the time course of induction of cytochrome P-450 by phenytoin. subjects received 200 mg of phenytoin every 8 h for 11 doses and 100 mg every 8 h for 8 doses. Trough concentrations of phenytoin in plasma were measured by HPLC. Urine samples were collected between 08:00 and 12:00 on days -1, 1, 2, 3, 4, 5, and 7. Urinary concentrations of 6 beta-hydroxycortisol (6 beta-OHC) and cortisol (C) were determined by HPLC and were reported as a ratio (6 beta-OHC/C); this ratio is a marker for the 3A isozyme family of cytochrome P-450 (CYP3A). Mean plasma phenytoin concentrations on day 7 were 15.4 +/- 7.20 micrograms/mL. Mean 6 beta-OHC/C ratios increased by a factor of 2.37 from baseline during the course of the study. Values for the ratios on days 4, 5, and 7 were significantly higher than baseline by Dunnett's test (one-sided) (p < 0.05); the day 3 value was borderline statistically significant. These results show that phenytoin rapidly induces the activity of the CYP3A family of isozymes, with effects apparent within 48 h after the initiation of phenytoin therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7616365     DOI: 10.1002/jps.2600840305

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

1.  Population pharmacokinetics of tirilazad: effects of weight, gender, concomitant phenytoin, and subarachnoid hemorrhage.

Authors:  J C Fleishaker; J Fiedler-Kelly; T H Grasela
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

Review 2.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

3.  A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio.

Authors:  D W Boulton; P Arnaud; C L DeVane
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

Review 4.  Troglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

5.  Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury.

Authors:  Robert A Roth; Omar Kana; David Filipovic; Patricia E Ganey
Journal:  Expert Opin Drug Metab Toxicol       Date:  2022-08-24       Impact factor: 4.936

6.  Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers.

Authors:  Stephanie Chhun; Celine Verstuyft; Nathalie Rizzo-Padoin; Guy Simoneau; Laurent Becquemont; Ilana Peretti; Alan Swaisland; Robert Wortelboer; Jean Francois Bergmann; Stephane Mouly
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 7.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

8.  Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation.

Authors:  M Hadjibabaie; S Rahimian; Z Jahangard-Rafsanjani; M Amini; K Alimoghaddam; M Iravani; A Ghavamzadeh; S Sadrai
Journal:  Daru       Date:  2011       Impact factor: 3.117

Review 9.  The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo.

Authors:  Dmitrij A Sychev; Ghulam Md Ashraf; Andrey A Svistunov; Maksim L Maksimov; Vadim V Tarasov; Vladimir N Chubarev; Vitalij A Otdelenov; Natal'ja P Denisenko; George E Barreto; Gjumrakch Aliev
Journal:  Drug Des Devel Ther       Date:  2018-05-08       Impact factor: 4.162

Review 10.  Role of intravenous levetiracetam in seizure prophylaxis of severe traumatic brain injury patients.

Authors:  Batool F Kirmani; Diana Mungall; Geoffrey Ling
Journal:  Front Neurol       Date:  2013-11-01       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.